Study shows prior viral infections can make Zika infection worse

March 31, 2017 by Bob Yirka report
Transmission electron micrograph (TEM) of Zika virus. Credit: Cynthia Goldsmith/Centers for Disease Control and Prevention

(Medical Xpress)—A team of researchers with the Icahn School of Medicine at Mount Sinai in New York City has found that mice who have survived a dengue or West Nile viral infection fare worse when subsequently infected with the Zika virus compared to those that have not had such prior infections. In their paper published in the journal Science, the team explains how they tested human plasma in lab dishes and in mice to learn more about the possible implications of Zika infections in people who have previously experienced other viral infections.

Prior research has shown that oftentimes when a person survives a , they fare worse with a second if it is a different kind. When humans and mice become infected with a virus, the body creates antibodies as a response. Such antibodies help protect against future infections. But in some cases, those same antibodies can cause a host to be less protected against a different virus from the same family due to an antibody-dependent enhancement reaction, which can leave those with initial infections at greater risk from secondary infections. In this new effort, the researchers looked at the possible implications of such reactions regarding Zika, because it is related to both dengue and West Nile.

The team ran two kinds of tests. In the first series, plasma samples were obtained from people who had been infected with dengue or West Nile and from people who had never had any related infections. The researchers found that when Zika was introduced to the plasma, it bound to the antibodies of those who had experienced dengue and West Nile infections (which meant it was more able to infect cells) but not to the antibodies of those that had never had either infection.

In the second series of tests, the researchers injected the (simulating prior infections) into mice and then watched to see what would happen after they were infected with Zika. They report that the survival rate for mice given plasma from a dengue infected person was just 20 percent, for West Nile it was 60 percent and for those that received plasma from donors who had never been infected the survival rate was 93 percent.

As the Zika virus continues to spread rapidly across the globe, it might pose a particular risk to people previously infected with two related viruses, dengue and West Nile, researchers at the Icahn School of Medicine at Mount Sinai have found. Their study, published in the journal Science, may help explain the severe manifestations of Zika virus infection observed in specific populations, including those in South America. Credit: Mount Sinai Health System

The researchers note their results are alarming because dengue is widespread in many parts of South America where Zika is spreading, and the same is true for West Nile in North America. The team plans to continue their studies looking for real-world cases of people infected with Zika who have experienced prior infections from dengue or West Nile to see if they fared worse.

Explore further: Pre-existing immunity to dengue virus shapes Zika-specific T cell response

More information: Susana V. Bardina et al. Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity, Science (2017). DOI: 10.1126/science.aal4365

Abstract
Zika virus (ZIKV) is spreading rapidly into regions around the world where other flaviviruses, such as dengue (DENV) and West Nile virus (WNV) are endemic. Antibody-dependent enhancement (ADE) has been implicated in more severe forms of flavivirus disease, but whether this also applies to ZIKV infection is unclear. Using convalescent plasma from DENV and WNV infected individuals, we found substantial enhancement of ZIKV infection in vitro that was mediated through IgG engagement of Fcγ receptors. Administration of DENV or WNV convalescent plasma into ZIKV-susceptible mice resulted in increased morbidity and mortality, including fever, viremia, and viral loads in spinal cord and testes. ADE may explain the severe disease manifestations associated with recent ZIKV outbreaks and highlights the need to exert great caution when designing flavivirus vaccines.

Related Stories

Pre-existing immunity to dengue virus shapes Zika-specific T cell response

March 13, 2017
Although Zika and dengue are considered different virus "species," they are so closely related that the immune system treats Zika just like another version of dengue, report researchers at La Jolla Institute for Allergy and ...

A single mutation may impact infectivity of West Nile and similar viruses

February 16, 2017
A mutation that impacts changes in the shape of an essential viral protein may influence the infectivity of West Nile and other viruses in the flavivirus family, according to a new study in PLOS Pathogens.

Study demonstrates how Zika virus rewires and repurposes invaded cells

March 30, 2017
New research reveals a high-resolution view of the Zika viral life cycle within infected cells and shows dramatic changes in the cell's architecture throughout the infection process. This novel perspective may lead to the ...

More evidence that Zika mRNA vaccines can stop viral replication in mice

February 17, 2017
Vaccine developers have successfully protected mice against Zika by injecting synthetic messenger RNA that encodes for virus proteins into the animals. The cells of the mice then build parts of the virus, training the immune ...

T cells join the fight against Zika

January 12, 2017
The worst of the global Zika virus outbreak may be over but many key questions remain, such as why the virus persists in certain tissues after the systemic infection has cleared; how does the immune system counteract the ...

Recommended for you

New cellular approach found to control progression of chronic kidney disease

December 15, 2017
Researchers have demonstrated for the first time that extracellular vesicles - tiny protein-filled structures - isolated from amniotic fluid stem cells (AFSCs) can be used to effectively slow the progression of kidney damage ...

Testing shows differences in efficacy of Zika vaccines after one year

December 15, 2017
(Medical Xpress)—A large team of researchers with members from Harvard Medical School, Walter Reed Army Institute of Research, Bioqual Inc. and MIT has found that the efficacy of the three types of Zika vaccines currently ...

How to regulate fecal microbiota transplants

December 15, 2017
(Medical Xpress)—A small team of researchers at the University of Maryland, some with affiliations to the Veterans Affairs Maryland Health Care System, has written and published a Policy Forum piece in the journal Science ...

Urine test developed to test for tuberculosis

December 14, 2017
(Medical Xpress)—An international team of researchers has developed a urine test that can be used to detect tuberculosis (TB) in human patients. In their paper published in Science Translational Medicine, the group describes ...

40 years after first Ebola outbreak, survivors show signs they can stave off new infection

December 14, 2017
Survivors of the first known Ebola outbreak, which occurred in the Democratic Republic of the Congo in 1976, may be key to development of vaccines and therapeutic drugs to treat future outbreaks, according to a new study ...

Aging impairs innate immune response to flu

December 13, 2017
Aging impairs the immune system's response to the flu virus in multiple ways, weakening resistance in older adults, according to a Yale study. The research reveals why older people are at increased risk of illness and death ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.